Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Economic aspects of chemotherapy
Autore:
Karlsson, G; Nygren, P; Glimelius, B;
Indirizzi:
Univ Uppsala Hosp, Sect Oncol, Dept Oncol Radiol & Clin Immunol, SE-75185 Uppsala, Sweden Univ Uppsala Hosp Uppsala Sweden SE-75185 unol, SE-75185 Uppsala, Sweden Stockholm Sch Econ, S-11383 Stockholm, Sweden Stockholm Sch Econ Stockholm Sweden S-11383 n, S-11383 Stockholm, Sweden
Titolo Testata:
ACTA ONCOLOGICA
fascicolo: 2-3, volume: 40, anno: 2001,
pagine: 412 - 433
SICI:
0284-186X(2001)40:2-3<412:EAOC>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
CELL LUNG-CANCER; BONE-MARROW TRANSPLANTATION; COST-EFFECTIVENESS ANALYSIS; NON-HODGKINS-LYMPHOMA; VINORELBINE PLUS CISPLATIN; ADVANCED OVARIAN-CARCINOMA; METASTATIC BREAST-CANCER; DECISION-ANALYSIS MODEL; ACUTE MYELOID-LEUKEMIA; FIRST-LINE THERAPY;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
77
Recensione:
Indirizzi per estratti:
Indirizzo: Glimelius, B Univ Uppsala Hosp, Sect Oncol, Dept Oncol Radiol & Clin Immunol, SE-75185 Uppsala, Sweden Univ Uppsala Hosp Uppsala Sweden SE-75185 5 Uppsala, Sweden
Citazione:
G. Karlsson et al., "Economic aspects of chemotherapy", ACTA ONCOL, 40(2-3), 2001, pp. 412-433

Abstract

A systematic review of the effect of chemotherapy in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU). The review also included an assessment of the limited number of studies available on the health economics of chemotherapy for diagnoses included in the SBU report. The conclusions reached from this assessment can be summarized as follows:Several international studies and one Swedish study addressed the cost-effectiveness of different chemotherapeutic regimens, The quality of the: studies is generally low and comparability is rather limited. Some of the studies compared cytostatic treatment with no cytostatic treatment. Most studies. however, compared two or more treatments. The costs were then compared with potential differences in treatment outcome. Outcomes are mostly measuredas the cost per life-year gained. The results from these studies vary by treatment and indication. In some cases, after all relevant costs are taken into account, chemotherapy shows cost savings. In most studies, chemotherapy is associated both with higher costs and improved treatment results, often measured in terms of survival. Studies of rather high quality show that the cost per life-year gained (quality-adjusted) for most chemotherapeutic regimens with relatively limited effects ranges between 100000 and 250000 Swedish kronor (SEK). Estimates ofcost-effectiveness for more effective chemotherapy has not been reported in the literature. The estimated costs are in parity with the costs of 'established' treatments for other diseases. There is uncertainty about what treatments can be considered cost-effective; there is no consensus concerning what costs are 'reasonable' per life-year gained in health care. The estimates of cost-effectiveness in most studies are highly uncertain and must he interpreted with caution. Improved assessment would require morestudies in Sweden. For various reasons it is difficult to apply the results from the international studies to Sweden.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/21 alle ore 16:22:40